Technical Analysis for ACHL - Achilles Therapeutics plc
Grade | Last Price | % Change | Price Change |
---|---|---|---|
F | 0.80 | -1.60% | -0.01 |
ACHL closed down 1.6 percent on Monday, July 1, 2024, on 12 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
NR7 | Range Contraction | 0.00% | |
Lower Bollinger Band Walk | Weakness | 0.00% | |
Inside Day | Range Contraction | 0.00% | |
Below Lower BB | Weakness | 0.00% | |
Lower Bollinger Band Touch | Weakness | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
Doji - Bullish? | Reversal | -1.60% | |
Lower Bollinger Band Walk | Weakness | -1.60% | |
Stochastic Reached Oversold | Weakness | -1.60% | |
Outside Day | Range Expansion | -1.60% |
Alert | Time |
---|---|
Down 1% | about 9 hours ago |
60 Minute Opening Range Breakdown | 3 days ago |
Down 1% | 3 days ago |
Rose Above Lower Bollinger Band | 3 days ago |
Down 5% | 4 days ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 08/02/2024
Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various types of solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. It is also developing products for use in the treatment of head and neck squamous cell carcinoma, renal cell carcinoma, triple negative breast cancer, and bladder cancer. The company was founded in 2016 and is headquartered in London, the United Kingdom.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Clinical Medicine Solid Tumors Cancer Treatment Cancer Immunotherapy Melanoma Antineoplastic Drugs Orphan Drug Breakthrough Therapy Bladder Cancer Head And Neck Cancer Renal Cell Carcinoma Advanced Non Small Cell Lung Cancer Head And Neck Squamous Cell Carcinoma Immuno Oncology Biopharmaceutical Triple Negative Breast Cancer
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Clinical Medicine Solid Tumors Cancer Treatment Cancer Immunotherapy Melanoma Antineoplastic Drugs Orphan Drug Breakthrough Therapy Bladder Cancer Head And Neck Cancer Renal Cell Carcinoma Advanced Non Small Cell Lung Cancer Head And Neck Squamous Cell Carcinoma Immuno Oncology Biopharmaceutical Triple Negative Breast Cancer
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 1.76 |
52 Week Low | 0.74 |
Average Volume | 118,836 |
200-Day Moving Average | 0.93 |
50-Day Moving Average | 0.87 |
20-Day Moving Average | 0.88 |
10-Day Moving Average | 0.85 |
Average True Range | 0.05 |
RSI (14) | 33.33 |
ADX | 22.06 |
+DI | 7.08 |
-DI | 13.67 |
Chandelier Exit (Long, 3 ATRs) | 0.80 |
Chandelier Exit (Short, 3 ATRs) | 0.94 |
Upper Bollinger Bands | 0.95 |
Lower Bollinger Band | 0.80 |
Percent B (%b) | -0.01 |
BandWidth | 16.70 |
MACD Line | -0.02 |
MACD Signal Line | -0.01 |
MACD Histogram | -0.0098 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 0.85 | ||||
Resistance 3 (R3) | 0.86 | 0.85 | 0.84 | ||
Resistance 2 (R2) | 0.85 | 0.83 | 0.84 | 0.84 | |
Resistance 1 (R1) | 0.82 | 0.82 | 0.82 | 0.82 | 0.84 |
Pivot Point | 0.81 | 0.81 | 0.81 | 0.81 | 0.81 |
Support 1 (S1) | 0.79 | 0.80 | 0.78 | 0.79 | 0.77 |
Support 2 (S2) | 0.78 | 0.79 | 0.78 | 0.76 | |
Support 3 (S3) | 0.76 | 0.78 | 0.76 | ||
Support 4 (S4) | 0.75 |